Objectives: Trauma-induced coagulopathy remains a significant contributor to mortality in severely injured patients. Fibrinogen is essential for early hemostasis and is recognized as the first coagulation factor to fall below critical levels, compromising the coagulation cascade. Recent studies suggest that early administration of fibrinogen concentrate is feasible and effective to prevent coagulopathy. We conducted a scoping review to characterize the existing quantity of literature and to explore the usage of prehospital fibrinogen concentrate products in improving clinical outcomes in trauma patients.
Methods: A search strategy was developed and underwent Peer Review of Electronic Search Strategies (PRESS) review in consultation with an information specialist. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Scopus from inception to May 6, 2024. English studies evaluating prehospital civilian and military usage of fibrinogen concentrate in trauma patients were included. Studies were assessed by three independent reviewers for meeting inclusion and exclusion criteria. A hand search of the reference lists of included articles was conducted to identify additional studies meeting inclusion criteria. Clinical endpoints regarding fibrinogen were extracted and synthesized.
Results: The literature search returned 1,301 articles with six studies meeting the inclusion criteria. Five studies (83%) were conducted in civilian settings and one study (17%) was conducted in a military setting. Of the included studies, two related studies (29%) utilized a randomized control trial design. We identified five outcomes that compared fibrinogen concentrate to a placebo group. The outcomes included thromboembolic events, clotting time, maximum clot firmness, clot stability at emergency department (ED) admission, and fibrinogen concentration at ED admission. Apart from thromboembolic events, all other reported outcomes showed statistically significant differences in group comparisons, determined using p values. The four (67%) non-clinical studies underscored the robustness, practicality, and degree of fibrinogen concentrate utilization in military environments and retrieval services.
Conclusions: Preliminary research suggests that prehospital fibrinogen concentrate administration in traumatic bleeding patients is both feasible and effective, improving clotting parameters. While implementing a time-saving and proactive approach with fibrinogen holds potential for enhancing trauma care, the current evidence is limited. Further studies in this novel field are warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/10903127.2024.2425819 | DOI Listing |
J Pak Med Assoc
January 2025
Department of Neurosurgery, Baoding No.1 Central Hospital, Baoding, China.
The retrospective study was conducted at Baoding No.1 Central Hospital, China, and comprised data from July 2021 to January 2023, and aimed at exploring the relationship of neuron-specific enolase, D-dimer and lactate dehydrogenase with prognosis in patients with serous traumatic brain injury. Data of 100 patients was categorised into favourable prognosis group A having 50(50%) patients and unfavourable prognosis group B having 50(50%) patients, and was compared with as many healthy controls in group C.
View Article and Find Full Text PDFEquine Vet J
January 2025
Department of Animal Medicine and Surgery, University of Cordoba, Cordoba, Spain.
Background: Endotoxaemia is a common condition in equids, frequently accompanied by alterations in haemostasis. Non-steroidal anti-inflammatory drugs, such as meloxicam, have been proven to alleviate some signs of endotoxaemia in donkeys. Neither the haemostatic response to induced endotoxaemia nor the effect of meloxicam in this regard have been described in donkeys.
View Article and Find Full Text PDFSisli Etfal Hastan Tip Bul
December 2024
Department of Radiation Oncology, University of Health Sciences Türkiye, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Türkiye.
Objectives: Nonsmall cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Asymmetric dimethylarginine (ADMA) is an emerging molecule that is highlighted in carcinogenesis and tumor progression in lung cancer. Since elevated concentrations of ADMA are observed in lung cancer patients, we aimed to explore its associations with inflammation markers and established prognostic indices.
View Article and Find Full Text PDFObjectives: To describe the clinical presentation and clinicopathological findings of dogs with nodular splenic lesions composed of heterogeneous cell components associated with systemic inflammation and to provide information on the outcome after surgical resection.
Materials And Methods: Medical records were searched for dogs with histologically and immunohistochemically characterised nodular splenic lesions with mixed stromal, histiocytic and lymphoid cells and the presence of systemic inflammatory markers at the time of diagnosis.
Results: Four dogs were included, of which three had an undifferentiated splenic stromal sarcoma and one had a splenic leiomyosarcoma.
Thromb Haemost
January 2025
Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland.
Background: Asthma is associated with a prothrombotic state. Plasma factor VIIa-antithrombin complex concentrations (FVIIa-AT) indirectly reflect the interaction of tissue factor (TF) with FVII. Since TF is a key initiator of coagulation in vivo, we hypothesized that FVIIa-AT are higher in asthma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!